| Date | Time | Source | Headline | Symbol | Company |
| 08/29/2005 | 8:25PM | PR Newswire (US) | Novogen Sales Up, Clinical Trial Results Emerging | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 07/12/2005 | 1:36PM | PR Newswire (US) | Australian Investigational Product Promotes Healing in Venous Stasis Ulcers | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 05/10/2005 | 10:07AM | PR Newswire (US) | Preliminary Results of Multi-Center Trial Indicate That 33 Percent of Late- Stage Refractory Ovarian Cancer Patients Experience | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 02/25/2005 | 11:46AM | PR Newswire (US) | Novogen Sales Up, Significant Advances With Clinical Trial Program | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 02/25/2005 | 8:00AM | PR Newswire (US) | Novogen Limited Appoints New Director | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 02/17/2005 | 8:00AM | PR Newswire (US) | Novogen Patent License to Solae Now Transferred to ADM | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 01/26/2005 | 8:37AM | PR Newswire (US) | FDA Grants Fast Track Designation for Phenoxodiol in Oral Dosage Form for Prostate Cancer | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 01/24/2005 | 8:44AM | PR Newswire (US) | Phenoxodiol Increases the Effectiveness of Docetaxel by at Least 100 Times | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 01/18/2005 | 8:54AM | PR Newswire (US) | Novogen Receives Royalty Payment From Solae LLC | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 01/18/2005 | 8:53AM | PR Newswire (US) | Novogen Reaches Settlement With GNC on Isoflavone Patent Infringement Case | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 11/22/2004 | 8:29AM | PR Newswire (US) | Researchers Report That Oral Phenoxodiol Slows Disease Progression in Late-Stage Prostate Cancer Patients | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 11/04/2004 | 9:28AM | PR Newswire (US) | FDA Grants Marshall Edwards, Inc. Fast-Track Designation for Phenoxodiol for Recurrent Ovarian Cancer | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 07/06/2004 | 10:04AM | PR Newswire (US) | Novogen Cardiovascular Drug Enters Second Human Clinical Trial | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 06/14/2004 | 10:45AM | PR Newswire (US) | Marshall Edwards, Inc., Names Second Study Site in Multi-National Ovarian Cancer Trial of Investigational Anti-Cancer Drug Pheno | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 05/20/2004 | 9:39AM | PR Newswire (US) | Novogen Patent Granted in Canada | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 05/18/2004 | 9:28AM | PR Newswire (US) | The University of Sydney Honors Marshall Edwards Inc. Chairman | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 05/12/2004 | 10:14AM | PR Newswire (US) | Novogen's Second Investigational Anti-Cancer Drug Enters Human Clinical Trials | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 04/21/2004 | 9:51AM | PR Newswire (US) | New Trial to Evaluate Phenoxodiol as Chemo-Sensitizing Agent in Patients With Chemo-Resistant Ovarian Cancer | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 03/31/2004 | 9:00AM | PR Newswire (US) | Investigational Anti-Cancer Drug Phenoxodiol Produces Response and Restores Chemo-Sensitivity In Four Studies | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 03/26/2004 | 8:58AM | PR Newswire (US) | Late Breaking Clinical Trial Results of Investigational Anti-Cancer Drug Phenoxodiol Among Four Abstracts to be Presented at Ame | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 03/08/2004 | 9:57AM | PR Newswire (US) | Marshall Edwards, Inc. Commences Renal Cancer Human Trial of Phenoxodiol in Combination Therapy | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 02/23/2004 | 8:23AM | PR Newswire (US) | Marshall Edwards, Inc. Commences Clinical Trial in Cervical Cancer at Yale | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 02/09/2004 | 8:28AM | PR Newswire (US) | Investigational Anti-Cancer Drug, Phenoxodiol, Produces Promising Results in Women with Recurrent Ovarian Cancer | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 12/18/2003 | 9:13AM | PR Newswire (US) | Marshall Edwards, Inc. Announces Pricing of Initial Public Offering of 2,080,000 of Common Stock Units at $7.50 Per Unit | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 12/04/2003 | 3:43PM | PR Newswire (US) | Novogen's Marshall Edwards Inc. Subsidiary Receives US$10.1 Million From Warrants Exercised | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 12/03/2003 | 9:55AM | PR Newswire (US) | Novogen Gains New US Health Supplement Patent And Receives Milestone Payment | NASDAQ:KZIA | Kazia Therapeutics Ltd |
| 11/19/2003 | 9:25AM | PR Newswire (US) | Novogen Granted U.S. Patent Covering Phenoxodiol for Cancer Treatment | NASDAQ:KZIA | Kazia Therapeutics Ltd |